• Asger Granfeldt, Birthe Sindberg, Dan Isbye, Jesper Kjærgaard, Camilla M Kristensen, Søren Darling, Stine T Zwisler, Stine Fisker, Jens Christian Schmidt, Hans Kirkegaard, Anders M Grejs, Jørgen R G Rossau, Jacob M Larsen, Bodil S Rasmussen, Signe Riddersholm, Kasper Iversen, Martin Schultz, Jakob L Nielsen, Bo Løfgren, Kasper G Lauridsen, Christoffer Sølling, Kim Pælestik, Anders G Kjærgaard, Dorte Due-Rasmussen, Fredrik Folke, Mette G Charlot, JepsenRikke Malene H GRMHGDepartment of Anesthesiology, Zealand University Hospital, Køge, Denmark., Sebastian Wiberg, Maria Høybye, Mathias J Holmberg, and Lars W Andersen.
• Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
• Resuscitation. 2022 Jun 1; 175: 67-71.

ObjectiveThe primary results from the Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial have previously been reported. The objective of the current manuscript is to report long-term outcomes.MethodsThe VAM-IHCA trial was a multicenter, randomized, double-blind, placebo-controlled trial conducted at ten hospitals in Denmark. Adult patients (age ≥ 18 years) were eligible for the trial if they had an in-hospital cardiac arrest and received at least one dose of epinephrine during resuscitation. The trial drugs consisted of 40 mg methylprednisolone (Solu-Medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of epinephrine. This manuscript report outcomes at 6 months and 1 year including survival, survival with favorable neurological outcome, and health-related quality of life.Results501 patients were included in the analysis. At 1 year, 15 patients (6.3%) in the intervention group and 22 patients (8.3%) in the placebo group were alive corresponding to a risk ratio of 0.76 (95% CI, 0.41-1.41). A favorable neurologic outcome at 1 year, based on the Cerebral Performance Category score, was observed in 14 patients (5.9%) in the intervention group and 20 patients (7.6%) in the placebo group (risk ratio, 0.78 [95% CI, 0.41-1.49]. No differences existed between groups for favorable neurological outcome and health-related quality of life at either 6 months or 1 year.ConclusionsAdministration of vasopressin and methylprednisolone, compared with placebo, in patients with in-hospital cardiac arrest did not improve long-term outcomes in this trial.Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

19 keywords...

hide…